Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Varsha Gandhi, PhD, on Ibrutinib

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Aug
21
Today In Oncology
Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced, Refractory Malignancies
Mosunetuzumab With Response-Adapted Therapy in Previously Untreated NHL
Study Supports Personalized Weight-Loss Intervention for Breast Cancer Survivors
Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment
County-Level Medical Debt Linked to Advanced-Stage Cancers, Worse Survival Among Newly Diagnosed U.S. Adults
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo